

ASX Announcement

14 May 2021

Cogstate Limited
ABN 80 090 975 723

Suite 117
425 Smith Street
Fitzroy Victoria 3065
Australia

P +61 3 9664 1300
F +61 3 9664 1301
W cogstate.com

Unquoted Securities Update – Unquoted Options Forfeited/Expire

Cogstate (ASX:CGS) advises that, due to cessation of employment or the expiration of the option, the following number of Unrestricted Unquoted Options have been forfeited by participants in the Cogstate Employee Option Plan:

ASX Code	Security Name	Number before Lapse	Lapsing Options	Number after Lapse
CGSAU	Option expiring various dates ex various prices	7,098,333	(100,000)	6,998,333
CGSAV	Option expiring 30 Apr 2025 Ex 38c	-		-
CGSAW	Option expiring 30 Apr 2025 Ex 32c	50,000		50,000
CGSAX	Option expiring 15 Sep 2025 Ex 69c	655,437		655,437
CGSAY	Option expiring 15 Sep 2025 Ex 69c	1,310,873		1,310,873
CGSAZ	Option expiring 31 Oct 2025 Ex 78c	1,050,000	(100,000)	950,000
CGSAAA	Option expiring 28 Feb 2026 Ex \$1.00	600,000		600,000
CGSAAB	Option expiring 28 Aug 2026 Ex \$1.00	1,400,000		1,400,000
		12,164,643	(200,000)	11,964,643

This announcement was authorised for release by a sub-committee of the Board of Directors of Cogstate Ltd.

About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets. In October 2020, Cogstate extended its agreement with Eisai to the Rest of the World. The product, branded as NouKNOW, launched in Japan on 31 March 2020 (nouknow.jp). For more information, please visit www.cogstate.com.

For further information contact:

Brad O'Connor, Chief Executive Officer, boconnor@cogstate.com